Open AccessOncolytic effect of SARS‐CoV‐2 in a patient with mycosis fungoides: A case report
Author(s) -
Ohadi Laya,
Hosseinzadeh Fatemeh,
Dadkhahfar Sahar,
Nasiri Soheila
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5682
Subject(s) - mycosis fungoides , medicine , dermatology , oncolytic virus , disease , covid-19 , etiology , cutaneous t cell lymphoma , pathology , cancer , lymphoma , infectious disease (medical specialty)
The most common variant of cutaneous T‐cell lymphomas (CTCL) is mycosis fungoides (MF). Patients with MF often experience a chronic course of disease. The spontaneous regression (SR) of MF is rare, and the factors that predict SR have not been recognized yet. Here, we are reporting a case of persistent MF who had prominent remission after COVID‐19. This case report supports the possible antineoplastic effect of SARS‐CoV‐2. Understanding the underlying etiology of such effect can result in development of new target therapies for MF.